A 503B outsourcing facility is a place registered with the Food and Drug Administration (FDA) that prepares compounded medicines, including stock for clinics to use as patients need it. Compounding means mixing or altering ingredients to make a medication. The name describes the facility's rules and responsibilities; it doesn't mean FDA has reviewed each medicine it makes.

People often call this a “503B pharmacy.” That shorthand is useful, but the official term is “outsourcing facility.” The distinction matters when someone says where a prescribed medication comes from.

The 503B outsourcing facility definition

Congress created this category through the Drug Quality and Security Act, signed November 27, 2013. Section 503B of the Federal Food, Drug, and Cosmetic Act defines a facility at one location that compounds sterile drugs, elects to register with FDA, and meets the section's requirements. “Sterile” means free of living microorganisms, such as bacteria and fungi.

Under federal law, the facility needn't be a licensed pharmacy, although compounding must happen under a licensed pharmacist's direct supervision or be done by that pharmacist. State licensing requirements still matter. Registering is voluntary; meeting the requirements after choosing this route isn't optional.

FDA's outsourcing-facility overview describes the main obligations:

  • Manufacturing controls: current good manufacturing practice, or CGMP, means federal requirements for how drugs are made and controlled.
  • FDA inspections: scheduled according to risk, including the facility's history and the drugs it prepares.
  • Reporting: adverse events, meaning unwanted medical problems associated with a drug, must be reported as required. Product reports go to FDA at registration and twice yearly, in June and December.
  • Ongoing registration: the facility renews its registration annually.

For someone discussing tirzepatide with a provider, those are useful facts about the supplier. They don't establish whether the medication fits that person. Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.

Why the term exists

The turning point was the 2012 outbreak linked to contaminated steroid injections from the New England Compounding Center. Patients developed fungal meningitis, an infection involving the membranes around the brain and spinal cord, and other infections. CDC's final summary, reviewed October 30, 2015, records 753 cases across 20 states and 64 deaths.

The records behind each batch mattered during the response. A 2015 study by Smith and colleagues in Emerging Infectious Diseases describes efforts to notify 13,534 potentially exposed people. It estimated that the recall prevented another 3,150 contaminated injections.

There had been other failures, too. Mikosz and colleagues, writing in the same journal in 2014, investigated separate outbreaks of fungal eye infections associated with two contaminated compounded products. These events help explain the attention to how sterile medicines are prepared and traced.

FDA's account of the law says Congress acted in response to the meningitis outbreak and other serious incidents. Section 503B created a federal framework for facilities supplying compounded medicines, including stock for hospitals and clinics.

How 503B shows up in a peptide prescription

Peptides are short chains of amino acids, the building blocks of proteins. Some peptide medicines, including semaglutide and tirzepatide, are commonly discussed as GLP-1 medications because they act on a hormone pathway involved in blood sugar and appetite. Their ingredient names alone don't tell you which compounding route applies.

A prescription prepared specifically for one person usually follows the 503A route: a state-licensed pharmacy fills a named patient's prescription, with state-board oversight and applicable United States Pharmacopeia (USP) standards, the published standards for preparing medicines. Limited preparation ahead of prescriptions is possible. A 503B facility can instead supply office stock, meaning medicine a clinic holds before knowing which patient will receive it. FDA's comparison of the two sections sets out that distinction; our peptide compounding pharmacy guide explains the comparison in more detail.

A licensed provider may still prescribe a compounded formulation where lawful and clinically appropriate; that decision is between the patient and the doctor. The pharmacy must separately meet the rules for filling it. Semaglutide through Promise is also dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.

What the GLP-1 ingredient proposal covers

As of September 10, 2026, the day this article was written, FDA's June 26 notice gave July 30, 2026 as the extended comment deadline for its April 30 proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list. “Bulk drug substances” means raw active ingredients used to make medicines. That proposal concerns ingredients used by outsourcing facilities; it does not rewrite the separate 503A pathway. The 503B GLP-1 proposal explained covers its scope and next steps.

Three common mistakes with 503B

Treating registration as a product endorsement. A compounded drug from an outsourcing facility is not FDA-approved. FDA's registration questions and answers says registration alone also doesn't establish compliance with manufacturing requirements. A facility's name on a list and a finished medicine's review status answer different questions.

Assuming registered means inspected. As of September 10, 2026, the day this article was written, FDA's facility register, marked “Updated as of 9/8/2026,” included entries marked “Not yet inspected.” It lists individual addresses and inspection information. A Form 483, the document recording an inspector's observations, is not a final finding of a violation; the table's notes explain that distinction.

Reading office stock as permission to skip a prescription. A clinic can obtain qualifying 503B stock without naming each future patient. Dispensing a prescription drug to a patient still requires a prescription. That distinction applies when someone asks about compounded tirzepatide just as it does for other prescription medicines.

The useful details are the actual compounder's identity, the dispensing pharmacy, the medication's batch information and a working contact for questions. Our guide to how compounded medications are made follows the preparation and labeling steps.

The 503A bulks list concerns ingredients for the patient-specific pathway. It is separate from the 503B list. FDA Category 2 describes an interim policy category for nominated ingredients that raise significant safety concerns; a category number isn't a facility registration.

FDA tentative approval is different again: it describes a drug application whose scientific review is complete but whose effective approval is held back by a legal barrier. It isn't a waiting stage for a compounded prescription.

At Promise, a licensed provider reviews every request, and not everyone qualifies. The facility category helps explain who prepares a medicine and which rules apply; the visit establishes whether there is an appropriate prescription for that person.